NervGen Pharma Corp. (NGEN)
NASDAQ
$1.98−$0.0400 (−1.98%) on the dayAs of the close; data may be delayed.
NGEN price, last 12 months
Key stats
- Previous close
- $2.02
- Open
- $1.99
- Day range
- $1.86 – $2.01
- 52-week range
- $1.58 – $6.30
- Volume
- 331.7K
- Avg volume (20 days)
- 554.1K
- Market cap
- $208.6M
Performance
1W−3.4%
1M−10.4%
3M+5.9%
6M−45.9%
YTD—
1Y—
Technicals and fundamentals
About NervGen Pharma Corp.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
- Listed on
- NASDAQ
- Market cap
- $208.6M